United States Patent 10,420,749 (Lorlatinib Free Base Crystalline Form): Scope, Claim-by-Claim Boundaries, and US Patent Landscape
US Drug Patent 10,420,749 covers a specific crystalline polymorph of (10R)-lorlatinib free base defined by PXRD peak positions, reinforced by Raman and solid-state NMR (13C, 19F) spectral windows, plus protection for formulation and treatment methods for ALK/ROS1-driven cancers (including NSCLC). The estate sits in a patent space where (1) crystalline-form claims can block generic entry even after composition-of-matter protection expires, and (2) method-of-use claims can support infringement allegations when an ANDA/505(b)(2) product uses the claimed form and is labeled for the claimed indications.
What claims define the crystalline form scope of US Patent 10,420,749?
Direct answer (scope): The claims are limited to lorlatinib free base crystals that match specific powder X-ray diffraction (PXRD) 2θ peak sets (with tight tolerances), and in dependent claims are further limited by Raman wavenumbers and 13C/19F solid-state NMR resonance windows. Downstream claims (composition and method) depend on that crystalline-form predicate.
Claim set overview
Independent claim
- Claim 1: crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile free base with PXRD peaks at:
- 2θ = 9.6°, 10.1°, 16.2° each at ±0.2°
PXRD refinement dependents
- Claim 2: adds PXRD peak at 17.3° ±0.2°
- Claim 3: adds PXRD peak at 14.3° ±0.2°
Spectroscopy refinement dependents
- Claim 4: Raman bands at 2229 and 2240 cm−1 ±2 cm−1
- Claim 5: 13C ssNMR resonances at 39.1 and 142.1 ppm ±0.2 ppm
- Claim 6: 19F ssNMR resonances at −108.2 and −115.2 ppm ±0.2 ppm
“Mirror” claims on Raman / NMR predicates
- Claims 7–10: crystalline form characterized by Raman bands (2229 and 2240 cm−1 ±2) with further additions at:
- 1619 cm−1 ±2 (Claim 8)
- 1553 cm−1 ±2 (Claim 9)
- 774 cm−1 ±2 (Claim 10)
- Claims 11–16: crystalline form characterized by 13C ssNMR starting with 39.1 and 142.1 ppm ±0.2, then adding:
- 112.3 ppm ±0.2 (Claim 14)
- 25.8 ppm ±0.2 (Claim 15)
- 117.7 ppm ±0.2 (Claim 16)
- Claim 17: 19F ssNMR resonance is either −108.2 or −115.2 ppm ±0.2 (selected from a stated group)
Key boundary features that constrain infringement
-
Polymorph specificity via PXRD
- Claim 1 requires a crystalline form that exhibits at least the three defining PXRD peaks at specified 2θ positions within ±0.2°.
- A generic form (or different polymorph) that misses one of these peaks (or shifts them beyond the tolerance) can avoid literal infringement.
-
Dependent claims tighten the match
- Claims 2 and 3 add additional required PXRD peaks. A product matching Claim 1 but not the additional peaks could infringe Claim 1 yet fall outside Claims 2 or 3.
-
Orthogonal identity confirmation
- Raman (Claims 4, 7–10) and ssNMR (Claims 5–6 and 11–17) act as secondary “fingerprints.”
- The claim text you provided reads as if spectroscopy is part of the crystalline-form definition in the dependent claims. Practically, that creates evidentiary leverage: accused products must align in multiple analytical modalities.
-
Free base focus
- The subject matter is lorlatinib free base, not salts (no hydrochloride, sulfate, etc., in the claim set shown). A salt route can be a non-infringing design choice if it avoids use of the claimed free base crystalline form (though downstream “in situ” transformations can become factual issues in litigation).
How do the Raman and solid-state NMR limitations affect claim strength?
Direct answer: The spectroscopy windows are tight (±2 cm−1 for Raman; ±0.2 ppm for ssNMR), which typically narrows literal coverage to a highly specific crystal lattice. This can be strong for enforceability but also increases the need for clean analytical testing and dispute-ready reference standards.
Raman limitation clusters (Claims 4, 7–10)
- Base Raman signature for the crystal:
- 2229 and 2240 cm−1 ±2 cm−1 (Claims 4 and 7)
- Additional required Raman peaks (dependent):
- 1619 ±2 (Claim 8)
- 1553 ±2 (Claim 9)
- 774 ±2 (Claim 10)
Practical implication for scope
- If an accused sample produces Raman bands that shift outside ±2 cm−1 (due to instrument calibration, laser settings, sample prep, or polymorph differences), it can create noninfringement arguments against the Raman-dependent claims.
13C ssNMR limitation clusters (Claims 5, 11–16)
- Defining 13C ssNMR resonances:
- 39.1 and 142.1 ppm ±0.2 ppm (Claims 5 and 11)
- Additional dependent resonances:
- 112.3 ppm ±0.2 (Claim 14)
- 25.8 ppm ±0.2 (Claim 15)
- 117.7 ppm ±0.2 (Claim 16)
Practical implication
- ±0.2 ppm is restrictive. In disputes, expert comparison can turn on whether the accused material has the same polymorph or exhibits additional peaks from disorder/impurities.
19F ssNMR limitation clusters (Claims 6, 12–13, 17)
- Pair signature:
- −108.2 and −115.2 ppm ±0.2 (Claims 6 and 12)
- Broader “two or more resonance values” version:
- Claim 13 includes two or more resonances consisting of 39.1 and 142.1 ppm ±0.2 (note: this claim text as provided appears internally inconsistent because it is labeled 13C ssNMR; it repeats 39.1/142.1 and then adds 112.3/25.8/117.7 in later dependents, which is coherent for 13C but not for 19F. The numbering you supplied still functions as a claim-scope definition set for those specific carbon resonances.)
- Single-selection 19F version:
- Claim 17 requires 19F resonance at either −108.2 or −115.2 within ±0.2 (but “selected from” the group implies a match to at least one of the two peaks)
Practical implication
- Claim 17 has a looser functional requirement than Claims 6/12 because it accepts a match to one of the two listed 19F resonances. That can broaden literal coverage if the accused form shows one but not both.
What pharmaceutical composition claims are covered?
Direct answer: Claim 18 covers the crystalline form plus a pharmaceutically acceptable carrier/excipient.
- Claim 18: pharmaceutical composition comprising the crystalline form of claim 1 and an excipient.
Scope notes
- Composition claims can capture finished dosage forms and intermediates formulated under the same crystalline-form predicate, assuming the product uses the claimed polymorph of the free base.
What method-of-use claims are covered for ALK/ROS1 cancers?
Direct answer: The method claims require administration of the claimed crystalline form to treat abnormal cell growth cancer mediated by ALK or ROS1, explicitly including NSCLC.
Method claims
- Claim 19: treating abnormal cell growth in a mammal by administering a therapeutically effective amount of the crystalline form (claim 1), where the cancer is mediated by:
- Claim 20: the cancer is non-small cell lung cancer (NSCLC)
Scope notes
- The indication language matches the labeled therapeutic use for lorlatinib in ALK-positive metastatic NSCLC and ROS1-positive contexts (depending on label at the relevant time).
- In ANDA or 505(b)(2) cases, method-of-use infringement can depend on the asserted product’s labeling and patient population. If the accused product does not instruct use for the claimed ALK/ROS1 indications, enforcement of method claims can be harder.
How many distinct crystalline-form “sub-claims” exist within US 10,420,749?
From the text provided, the patent effectively establishes multiple overlapping identity anchors:
- PXRD-defined core (Claim 1, plus PXRD dependents Claim 2 and Claim 3)
- Raman-defined variants (Claim 4; and separate Raman branch Claims 7–10)
- 13C ssNMR-defined variants (Claim 5; and separate 13C branch Claims 11–16)
- 19F ssNMR-defined variants (Claim 6; Claims 12 and 17)
Infringement posture
- An accused product that matches the PXRD core (Claim 1) risks infringement regardless of whether it also matches the Raman/NMR branches, because those branches are dependent. However, dependent claims can be used to strengthen the evidentiary case and widen coverage against partial analytical mismatches.
What generic entry risks exist if a company files to use lorlatinib free base polymorphs?
Direct answer: The principal risk is a polymorph-identity match to Claim 1 (PXRD peak set), because Claim 1 is the foundational crystalline-form limitation for the composition and method claims.
Scenario mapping: where a generic could design around
- Avoidance strategy A: choose a different polymorph
- If the ANDA/505(b)(2) manufacturer selects a crystalline form whose PXRD peaks differ (missing peaks or peak shifts beyond ±0.2°), it can avoid Claim 1.
- Avoidance strategy B: use salt or different physical form
- Since the claims are for lorlatinib free base, a salt form could avoid direct literal infringement, assuming it is not transformed into the claimed free base polymorph in a way relevant to administration.
- Avoidance strategy C: match only partial spectroscopic features
- Dependent Raman/ssNMR claims require additional spectral matches; a candidate that matches Claim 1 by PXRD but not all Raman/NMR dependents still risks Claim 1 infringement.
- A candidate that avoids Claim 1 likely avoids the composition and method claims because those depend on claim 1.
Litigation leverage points created by the claim structure
- Tight analytical ranges create a clear infringement checklist.
- Independent Claim 1’s PXRD window is likely the first proving step, with Raman/ssNMR serving as corroboration for expert testimony and claim chart mapping.
How does US 10,420,749 likely fit in lorlatinib’s broader US patent estate?
Direct answer: US 10,420,749 is best categorized as a crystalline form / solid-state form patent on lorlatinib free base, positioned to extend exclusivity beyond initial compound coverage by protecting a specific polymorph used for drug substance and/or drug product.
What that means for competitive landscape
- Even if composition-of-matter patents on lorlatinib have expired, solid-state patents like this can still:
- block generics targeting the same polymorph,
- drive licensing settlements around the protected form,
- support Orange Book-listed blocking or non-blocking challenges depending on listing and patent assertion strategy.
When does US 10,420,749 lose exclusivity?
No USPTO/Orange Book expiry date information is provided in the inputs you supplied, so no expiration timeline can be stated from the claims alone. The patent’s loss of exclusivity is governed by its filing and priority dates, any term adjustments, and whether the patent is tied to listed regulatory exclusivity in the Orange Book.
Patent estate diligence checklist tied to this patent’s claim scope (US-focused)
Direct answer: A credible challenge or freedom-to-operate analysis for a lorlatinib generic or biosimilar-adjacent competitor must test the exact free base crystalline form used and compare it to Claim 1’s PXRD set, then map which downstream dependent claims are implicated.
What to test (and how it maps to the claims)
- PXRD: verify 2θ peaks at 9.6°, 10.1°, 16.2° (±0.2°) for claim 1; check for 14.3° and 17.3° (±0.2°) for claims 3 and 2.
- Raman: confirm 2229 and 2240 cm−1 ±2 cm−1; then assess additional peaks (1619, 1553, 774) for dependent claims.
- 13C ssNMR: confirm 39.1 and 142.1 ppm ±0.2; then test for additional listed resonances (112.3, 25.8, 117.7).
- 19F ssNMR: confirm −108.2 and/or −115.2 ppm ±0.2, noting the broader “selected from” structure in Claim 17.
How to map infringement
- If PXRD matches Claim 1, composition (Claim 18) and method (Claims 19–20) become reachable, subject to labeling/use facts.
- If PXRD fails Claim 1, the dependent claim chains typically collapse because they depend on Claim 1’s crystalline-form definition.
Key Takeaways
- US 10,420,749 is a crystalline-form patent on lorlatinib free base, anchored by Claim 1’s PXRD peak set at 9.6°, 10.1°, 16.2° (±0.2°).
- Dependent claims tighten identity with additional PXRD peaks and orthogonal confirmation using Raman (±2 cm−1) and solid-state NMR (±0.2 ppm).
- The patent extends beyond drug substance to Claim 18 (formulation) and Claims 19–20 (ALK/ROS1 and NSCLC method-of-use), all depending on the Claim 1 crystalline form.
- For generic or competitor risk, the decisive question is whether the accused lorlatinib free base polymorph matches Claim 1 PXRD. If it does not, literal coverage of the composition and method claims is unlikely to persist.
FAQs
1) Does US 10,420,749 protect salts of lorlatinib or only the free base?
Only lorlatinib free base is recited in the claim language you provided.
2) Which claim is the strongest “gatekeeper” for infringement coverage?
Claim 1, because composition and method claims depend on it and it defines the core PXRD fingerprint.
3) If a material matches the Raman peaks but not the PXRD peaks, does it infringe?
The dependent Raman claims you provided are tied to the crystalline form defined by the claim chain; without matching Claim 1’s PXRD-defined crystalline form, literal infringement through those dependent provisions is unlikely.
4) Can a competitor avoid infringement by switching to a different lorlatinib polymorph?
Yes, if the alternative polymorph’s PXRD 2θ peaks do not match Claim 1 within the stated tolerances.
5) What labeling factors matter most for enforcing Claims 19–20?
The cancer indication language: ALK/ROS1-mediated abnormal cell growth and NSCLC. Enforcement of method claims typically tracks whether the product is prescribed/used for those labeled conditions.
References
- US 10,420,749. (Patent claims provided in prompt; full bibliographic details not supplied).
